Immunoglobulin binding protein, and affinity support using same
Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin κ chain binding activity.
1. An immunoglobulin binding protein, comprising at least one mutant of an immunoglobulin binding domain,
wherein the at least one mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 95% with the sequence set forth in SEQ NO:9, the amino acid sequence having substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, and optionally at least one of substitution of threonine at a position corresponding to the 35 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 42 nd position of the amino acid sequence set forth in SEQ ID NO:9 with lysine, and substitution of asparagine at a position corresponding to the 54 th position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine.
2. A polynucleotide encoding the immunoglobulin binding protein according to claim 1 .
3. A vector, comprising the polynucleotide according to claim 2 .
4. A transformant, transformant, comprising the vector according to claim 3 .
5. An affinity support, comprising a solid-phase support; and the immunoglobulin binding protein according to claim 1 bound to the solid-phase support.
6. A method, comprising:
isolating an antibody or a fragment thereof with the affinity support according to claim 5 .
7. Method for producing an immunoglobulin binding protein, the method comprising:
expressing the immunoglobulin binding protein according to claim 1 in a transformant comprising a vector comprising a polynucleotide encoding the immunoglobulin binding protein or a cell-free protein synthesis system, or chemically synthesizing the immunoglobulin binding protein.
8. A method for producing a mutant of an immunoglobulin binding domain, the method comprising:
providing a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 9 or an amino acid sequence having an identity of at least 95% therewith,
introducing into the polypeptide at least one mutation selected from the group consisting of substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, and optionally at least one of substitution of threonine at a position corresponding to the 35 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 42 nd position of the amino acid sequence set forth in SEQ ID NO:9 with lysine, and substitution of asparagine at a position corresponding to the 54 th position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine, to produce a mutant immunoglobulin binding domain having immunoglobulin κ chain binding activity.
9. A method for producing an affinity support, the method comprising:
immobilizing the immunoglobulin binding protein according to claim 1 on a solid-phase support.
10. The immunoglobulin binding protein according to claim 1 , wherein the amino acid sequence has substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, and substitution of threonine at a position corresponding to the 35 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine.
11. The immunoglobulin binding protein according to claim 1 , wherein the amino acid sequence has substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, and substitution of glycine at a position corresponding to the 42 nd position of the amino acid sequence set forth in SEQ II) NO:9 with lysine.
12. The immunoglobulin binding protein according to claim 1 , wherein the amino acid sequence has substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, and substitution of asparagine at a position corresponding to the 54 th position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine.
13. The immunoglobulin binding protein according to claim 1 , wherein the amino acid sequence has substitution of lysine at a position corresponding to the 26 th position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 34 th position of the amino acid sequence set forth in SEQ ID NO:9 with histidine, substitution of threonine at a position corresponding to the 35 position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, substitution of glycine at a position corresponding to the 42 nd position of the amino acid sequence set forth in SEQ NO:9 with lysine, and substitution of asparagine at a position corresponding to the 54 th position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine.